Clinical trials: Wet Macular Degeneration
Macular Degeneration
Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
This study is a phase 3, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration.
- Trial name
- VIEW1 (NCT00509795)
- Testing
- ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321)
- Where
- 188 sites in United States, Canada
- Volunteers
- 1,217 people
- Sponsor
- Regeneron Pharmaceuticals
Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration
Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial
Excessive vascular endothelial growth factor (VEGF) plays a key part in promoting neovascularization and edema in neovascular (wet) age-related macular degeneration (nAMD).
- Trial name
- NCT03066258
- Testing
- RGX-314
- Where
- 8 sites in United States
- Volunteers
- 42 people
- Sponsor
- REGENXBIO Inc.
Age Related Macular Degeneration, Choroidal Neovascular Membrane
A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)
The purpose of this study is to determine whether 2.0mg Ranibizumab is effective in the treatment of recurrent fluid.
- Conditions
- Age Related Macular Degeneration, Choroidal Neovascular Membrane, Subfoveal Neovascular Age-Related Macular Degeneration, Macular Degeneration
- Trial name
- SAVE (NCT01025232)
- Testing
- Ranibizumab
- Where
- 2 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- David M. Brown, M.D.
Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)
Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
Regeneron Pharmaceuticals developed a single-dose pre-filled syringe (PFS) to deliver 8 mg aflibercept. The PFS is a convenient device that contains the study medication that will be injected in your study eye.
- Trial name
- NCT05989126
- Testing
- aflibercept 8 mg PFS
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Regeneron Pharmaceuticals
Age-Related Macular Degeneration, Macular Degeneration
Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD
The purpose of this study was to collect ECG data after a single IVT injection of brolucizumab 6 mg in patients with neovascular age-related macular degeneration (nAMD).
- Conditions
- Age-Related Macular Degeneration, Macular Degeneration, Wet Macular Degeneration, Retinal Degeneration
- Trial name
- NCT03954626
- Testing
- brolucuzumab 6 mg IVT
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Macular Degeneration
Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)
This study examines the effect of intravitreally administered VEGF Trap in patients with wet AMD. The purpose of this trial is to assess the ocular and systemic safety and tolerability of repeated intravitreal doses of VEGF Trap…
- Trial name
- NCT00320788
- Testing
- aflibercept injection (VEGF Trap-Eye, BAY86-5321)
- Where
- 18 sites in United States
- Volunteers
- 159 people
- Sponsor
- Regeneron Pharmaceuticals
Age-Related Macular Degeneration
Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects
To assess the safety and efficacy of repeated intravitreal injections of DE-122 (low dose and high dose) given in combination with Lucentis® in subjects with wet age-related macular degeneration (AMD) compared with Lucentis®…
- Trial name
- NCT03211234
- Testing
- 2.0 mg DE-122 Injectable Solution + Lucentis, 4.0 mg DE-122 Injectable Solution + Lucentis, Lucentis
- Where
- 14 sites in United States, Philippines
- Volunteers
- 76 people
- Sponsor
- Santen Inc.
Macular Degeneration
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
The purpose of this study is to determine the safety and efficacy of different dosage regimens of pazopanib eye drops for the treatment of neovascular age-related macular degeneration.
- Trial name
- NCT01134055
- Testing
- pazopanib eye drops, ranibizumab intravitreal injection
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 510 people
- Sponsor
- GlaxoSmithKline
Wet Age-related Macular Degeneration
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
This Phase 3 study will evaluate the efficacy and safety of KSI-301 compared to aflibercept, in participants with neovascular (wet) age-related macular degeneration (wAMD)
- Trial name
- DAYLIGHT (NCT04964089)
- Testing
- KSI-301, Aflibercept
- Where
- 66 sites in United States, Puerto Rico
- Volunteers
- 557 people
- Sponsor
- Kodiak Sciences Inc
Wet Age-related Macular Degeneration
Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)
This is a phase 2 randomized, double -masked study comparing the efficacy of EYP-1901 at 2 dose levels: 2060 microgram (mcg) and 3090 mcg against aflibercept.
- Trial name
- DAVIO2 (NCT05381948)
- Testing
- EYP-1901, Aflibercept 2mg/0.05mL Inj,Oph
- Where
- 67 sites in United States
- Volunteers
- 161 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)
Age-related macular degeneration (AMD) is a leading cause of vision loss in adults. Abnormal blood vessels grow under the macula at the back of the eye, and also leak blood and fluid, which damages and scars the macula, affecting…
- Trial name
- NCT04480463
- Testing
- SCD411, Aflibercept
- Where
- 130 sites in United States, Australia and 12 more
- Volunteers
- 576 people
- Sponsor
- Sam Chun Dang Pharm. Co. Ltd.
Exudative Age-Related Macular Degeneration
ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients
The purpose of this study was to assess the safety, tolerability, and the effects of treatment on ocular outcomes following a single intravitreal administration of ESBA1008 compared with LUCENTIS® in patients with exudative…
- Trial name
- NCT01304693
- Testing
- ESBA1008 solution, Ranibizumab 0.5 mg
- Volunteers
- 376 people
- Sponsor
- Alcon Research
Exudative Age-related Macular Degeneration
Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD
The purpose of the study is to determine the safety and efficacy of 4 monthly injections of iSONEP given alone or in combination with Lucentis, Avastin or Eylea in subjects with wet Age-related Macular Degeneration (AMD).
- Trial name
- Nexus (NCT01414153)
- Testing
- 4.0 mg iSONEP, 0.5 mg iSONEP, 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea
- Where
- 44 sites in United States
- Volunteers
- 158 people
- Sponsor
- Lpath, Inc.
Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration
A previous pilot study demonstrated that commonly available glaucoma drops (dorzolamide-timolol) might decrease the amount of chronic swelling in patient with wet age-related macular degeneration who have been receiving…
- Trial name
- DAWN (NCT03034772)
- Testing
- Dorzolamide-timolol, Artificial tears
- Where
- 5 sites in United States
- Volunteers
- 52 people
- Sponsor
- Wills Eye
Choroidal Neovascularization, Age-Related Maculopathy
Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)
The study will evaluate the safety and efficacy of the intravitreal dexamethasone implant as adjunctive therapy to Anti-VEGF treatment in the study eye of treatment naïve subjects with choroidal neovascularization secondary to…
- Trial name
- NCT00775411
- Testing
- dexamethasone, ranibizumab
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 44 people
- Sponsor
- Allergan
Neovascular Age-Related Macular Degeneration
Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration
To compare brolucizumab to aflibercept in Chinese patients with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)
- Trial name
- NCT04047472
- Testing
- Brolucizumab 6mg, Aflibercept 2 mg
- Where
- 30 sites in China
- Volunteers
- 397 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-Related Macular Degeneration
A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration
Study GR40548 is a Phase III, randomized, multicenter, open-label (visual assessor [VA]-masked), active-comparator study designed to assess the efficacy, safety, and pharmacokinetics (PK) of 100mg/ml delivered via the Port…
- Trial name
- Archway (NCT03677934)
- Testing
- PDS Implant filled with 100 mg/mL Ranibizumab, Intravitreal Injections of 10 mg/mL Ranibizumab
- Where
- 77 sites in United States
- Volunteers
- 415 people
- Sponsor
- Hoffmann-La Roche
Neovascular Age-related Macular Degeneration (nAMD)
Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
The purpose of this study was to generate additional safety and effectiveness data in Indian neovascular age-related macular degeneration (nAMD) patients that more closely resemble the real-world population intended to be treated…
- Trial name
- NCT05269966
- Testing
- Injection Brolucizumab
- Where
- 10 sites in India
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-Related Macular Degeneration
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD
The objective of this study is to provide initial safety, tolerability and pharmacokinetics information of intravitreal administration of pegcetacoplan in order to support further development into larger Phase II studies for…
- Trial name
- ASAP II (NCT02461771)
- Testing
- Pegcetacoplan
- Where
- 4 sites in United States, Australia
- Volunteers
- 13 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Wet Macular Degeneration
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with…
- Trial name
- NCT03823287
- Testing
- Faricimab, Aflibercept
- Where
- 161 sites in United States, Canada and 13 more
- Volunteers
- 671 people
- Sponsor
- Hoffmann-La Roche